《公司業績》威高(01066.HK)半年純利11.98億元人民幣跌21.3% 中期息7.34分人民幣
威高股份(01066.HK)公布截至今年6月底止中期業績,營業額68.98億元人民幣(下同),按年跌2.6%。純利11.98億元,按年跌21.3%;每股盈利0.27元。派中期息0.0734元,上年同期派0.086元。
不計特殊項目,公司擁有人應佔純利約11.98億元,按年下跌約15.8%。2022年同期特殊項目為威高血液淨化向投資者發行新股,公司之股權由28.0871%攤薄至26.55%形成收益約1億元。
雖然今年上半年集團的經營業績略有波動,但管理層欣然看到,各主要產品的銷量增長強勁,集團的市場份額在快速增長,行業影響力在大幅提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.